Cystic Fibrosis Foundation awards $3.3 million to Polyphor AG

The funding will support a Phase 1b/2a clinical trial of inhaled murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa….

Philanthropy News Digest | https://philanthropynewsdigest.org/rss/feed/pndnews

Goto full post >>